Pfizer, Inc. (PFE) — Stock Price, Financials & Analysis

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Key Statistics — PFE

  • Latest Close: $26.62
  • Market Cap: $151.73B
  • P/E Ratio (TTM): 35.0
  • EPS (TTM): $0.76
  • Dividend Yield: 636.00%
  • Beta: 0.28
  • 52-Week High: $28.75
  • 52-Week Low: $23.58
  • Profit Margin: 6.8%
  • Return on Equity: 5.0%
  • Debt to Equity: 74.3

Sector: Healthcare — Drug Manufacturers - General

Income Statement — PFE

  • 2021: Revenue N/A, Net Income N/A
  • 2022: Revenue $101.17B, Net Income $31.37B
  • 2023: Revenue $59.55B, Net Income $2.12B
  • 2024: Revenue $63.63B, Net Income $8.03B
“”Wednesday, August 12, 2026
Minimaxmax⁡x∈Δmin⁡y∈Δ x⊤ ⁣A y=v∗\max_{x \in \Delta} \min_{y \in \Delta} \, x^\top\! A \, y = v^*maxx∈Δ​miny∈Δ​x⊤Ay=v∗§Zero-Sum∑i=1nui(s)=0    ∀ s∈S\textstyle\sum_{i=1}^{n} u_i(s) = 0 \;\; \forall \, s \in S∑i=1n​ui​(s)=0∀s∈S§Nash Eq.x∗⊤ ⁣Ay≥x∗⊤ ⁣Ay∗≥x⊤ ⁣Ay∗x^{*\top}\! A y \geq x^{*\top}\! A y^* \geq x^\top\! A y^*x∗⊤Ay≥x∗⊤Ay∗≥x⊤Ay∗§ExpectedE[u1]=x⊤ ⁣A y\mathbb{E}[u_1] = x^\top\! A \, yE[u1​]=x⊤Ay§RegretRT=max⁡i∑t=1Tuit−∑t=1TuattR_T = \max_i \sum_{t=1}^{T} u_i^t - \sum_{t=1}^{T} u_{a_t}^tRT​=maxi​∑t=1T​uit​−∑t=1T​uat​t​§LP Dualmin⁡y,ww    s.t.    Ay≤w⋅1\min_{y,w} w \;\; \text{s.t.} \;\; Ay \leq w \cdot \mathbf{1}miny,w​ws.t.Ay≤w⋅1§Payoffu1(i,j)=aij,    u2(i,j)=−aiju_1(i,j) = a_{ij}, \;\; u_2(i,j) = -a_{ij}u1​(i,j)=aij​,u2​(i,j)=−aij​§Minimaxmax⁡x∈Δmin⁡y∈Δ x⊤ ⁣A y=v∗\max_{x \in \Delta} \min_{y \in \Delta} \, x^\top\! A \, y = v^*maxx∈Δ​miny∈Δ​x⊤Ay=v∗§Zero-Sum∑i=1nui(s)=0    ∀ s∈S\textstyle\sum_{i=1}^{n} u_i(s) = 0 \;\; \forall \, s \in S∑i=1n​ui​(s)=0∀s∈S§Nash Eq.x∗⊤ ⁣Ay≥x∗⊤ ⁣Ay∗≥x⊤ ⁣Ay∗x^{*\top}\! A y \geq x^{*\top}\! A y^* \geq x^\top\! A y^*x∗⊤Ay≥x∗⊤Ay∗≥x⊤Ay∗§ExpectedE[u1]=x⊤ ⁣A y\mathbb{E}[u_1] = x^\top\! A \, yE[u1​]=x⊤Ay
0∑×$0 sometimesAlpha v0.1.0

The Shounya

HomeScreenerHeatmapSectorsDividendsCompareWatchlistPortfolioChartTechnicalScannerEarningsCorrelationSector AnalysisInsidersCongressNewsLearnAboutStatus
← Home← ScreenerChart TerminalTechnical
PFEHealthcare

Pfizer, Inc. — Healthcare · Drug Manufacturers - General

$26.62-0.43 (-1.59%)
Mkt Cap
$151.73B
P/E
35.0
EPS
$0.76
Beta
0.28
Yield
636.00%
52W Hi
$28.75
52W Lo
$23.58
Vol
42.0M

Price History

Chart Terminal →Technical Analysis →

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
75,000
HQ
New York, NY, United States
Web
pfizer.com

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Top Executives

NameTitleTotal Pay
Dr. Albert Bourla D.V.M., Ph.D.Chairman of the Board & CEO$9.1M
Mr. David M. DentonExecutive VP & CFO$4.8M
Dr. Chris Boshoff FMedSci, M.D., Ph.D.Chief Scientific Officer and President of Research & Development$5.2M
Mr. Douglas M. LanklerExecutive VP & Chief Legal Officer$4.6M
Mr. Aamir MalikExecutive VP & Chief U.S. Commercial Officer$4.9M
Ms. Jennifer B. DamicoSenior VP, Controller & Principal Accounting Officer—
Mr. Dennis P. HancockExecutive VP & Chief Information Officer—
Ms. Francesca M. DeMartinoChief Investor Relations Officer—
Ms. Payal Sahni BecherChief People Experience Officer & Executive VP—
Dr. Michael S. Vincent M.D., Ph.D.Senior VP and Chief Scientific Officer of Inflammation & Immunology—

Financial Statements

✓
Profitable
4/5 periods
✗
Revenue Growing
-1.6% latest, 1/3 up
✗
Earnings Growing
-3.2% latest, 1/3 up
✗
Pays Dividend
No dividends
✓
Positive Margin
6.8% net margin

Pfizer, Inc.

Healthcare \u00b7 Drug Manufacturers - General

Market Cap$151.73B
Trailing P/E35.0
Forward P/E9.2
EPS (trailing)$0.76
EPS (forward)$2.89
Gross Margin74.7%
Operating Margin27.9%
Profit Margin6.8%
Dividend Rate$1.72/share
Dividend Yield636.0%
Payout Ratio226.3%

Revenue & Net Income

2021 – 2025, Annual

Revenue

Net Income

Profit Margins

2021 – 2025, Annual

Earnings Per Share

2021 – 2025, Annual

Dividends

No dividend history available.

Price Ranges

52-Week
$23.58$28.75
Fwd P/E9.2
Avg Volume42.0M
Shares Out5.70B

Key Ratios

Gross Margin74.7%
Operating Margin27.9%
Profit Margin6.8%
ROE5.0%
ROA5.8%
P/B1.8
D/E74.25
Current Ratio1.27
Dividend Rate$1.72
Payout Ratio226.3%

Cash & Debt

Cash 16%Debt 84%
Total Cash$11.70B
Total Debt$63.48B
Net Cash$-51.78B
Free Cash Flow$12.49B
Operating CF$13.40B

Ratings Snapshot

2.5 / 5
P/E2/5(35.0)
P/B4/5(1.8)
ROE2/5(5.0)
ROA3/5(5.8)
D/E1/5(74.3)
Liquidity3/5(1.3)

Growth Pulse

Revenue Growth+2.6%

Analyst Recommendations

0m
Hold (28 analysts)
8
16
Strong Buy: 2
Buy: 8
Hold: 16
Sell: 1
Strong Sell: 1
MonthStr BuyBuyHoldSellStr Sell
0m281611
-1m281611
-2m291611
-3m291512

Income Snapshot 2025

Revenue
$62.6B
Net Income
$7.8B
Gross Margin
74.3%
Net Margin
12.4%
Op. Income
$17.4B
EPS
$1.37

Balance Sheet

2021 – 2025, Annual
Debt / Equity0.74x
Owns more than it owes — healthy
Current Ratio1.16x
Can cover short-term bills
Net Debt$62.82B
Total debt minus cash on hand

Assets vs Liabilities vs Equity

Assets = Liabilities + Equity. The green bar is what's left for shareholders after paying all debts.

Cash vs Debt

How much cash the company has on hand vs how much it owes in total debt.

Period Detail

PeriodAssetsLiabilitiesEquityCashDebtD/E
2021N/AN/AN/AN/AN/A—
2022$197.21B$101.29B$95.66B$416.0M$34.86B0.36x
2023$226.50B$137.21B$89.01B$2.85B$70.84B0.80x
2024$213.40B$124.90B$88.20B$1.04B$63.65B0.72x
2025$208.16B$121.39B$86.48B$1.14B$63.96B0.74x

Balance Sheet Snapshot 2025

Total Assets$208.16B
Total Liabilities$121.39B
Equity$86.48B
Retained Earnings$114.61B
Goodwill$71.26B
Long-Term Debt$60.81B

Cash Flow Statement

2021 – 2025, Annual

Operating · Investing · Financing

Operating — cash from core business.Investing — buying/selling long-term assets.Financing — debt, equity & dividends.

Free Cash Flow

Operating cash flow minus capital expenditure — the cash available after maintaining operations.

PeriodOperatingInvestingFinancingFCFCapEx
2021$0$0$0$0$0
2022$29B$-16B$-15B$26B$-3B
2023$9B$-32B$26B$5B$-4B
2024$13B$3B$-17B$10B$-3B
2025$12B$-1B$-10B$9B$-3B

Capital Allocation 2025

CapEx$2.63B
Dividends Paid$9.77B
BuybacksN/A
Debt Repaid$9.75B
Debt Issued$9.68B
Net Change Cash$49.0M

Price History

Chart Terminal →Technical Analysis →

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
75,000
HQ
New York, NY, United States
Web
pfizer.com

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Top Executives

NameTitleTotal Pay
Dr. Albert Bourla D.V.M., Ph.D.Chairman of the Board & CEO$9.1M
Mr. David M. DentonExecutive VP & CFO$4.8M
Dr. Chris Boshoff FMedSci, M.D., Ph.D.Chief Scientific Officer and President of Research & Development$5.2M
Mr. Douglas M. LanklerExecutive VP & Chief Legal Officer$4.6M
Mr. Aamir MalikExecutive VP & Chief U.S. Commercial Officer$4.9M
Ms. Jennifer B. DamicoSenior VP, Controller & Principal Accounting Officer—
Mr. Dennis P. HancockExecutive VP & Chief Information Officer—
Ms. Francesca M. DeMartinoChief Investor Relations Officer—
Ms. Payal Sahni BecherChief People Experience Officer & Executive VP—
Dr. Michael S. Vincent M.D., Ph.D.Senior VP and Chief Scientific Officer of Inflammation & Immunology—

Price Ranges

52-Week
$23.58$28.75
Fwd P/E9.2
Avg Volume42.0M
Shares Out5.70B

Key Ratios

Gross Margin74.7%
Operating Margin27.9%
Profit Margin6.8%
ROE5.0%
ROA5.8%
P/B1.8
D/E74.25
Current Ratio1.27
Dividend Rate$1.72
Payout Ratio226.3%

Cash & Debt

Cash 16%Debt 84%
Total Cash$11.70B
Total Debt$63.48B
Net Cash$-51.78B
Free Cash Flow$12.49B
Operating CF$13.40B

Ratings Snapshot

2.5 / 5
P/E2/5(35.0)
P/B4/5(1.8)
ROE2/5(5.0)
ROA3/5(5.8)
D/E1/5(74.3)
Liquidity3/5(1.3)

Growth Pulse

Revenue Growth+2.6%

Analyst Recommendations

0m
Hold (28 analysts)
8
16
Strong Buy: 2
Buy: 8
Hold: 16
Sell: 1
Strong Sell: 1
MonthStr BuyBuyHoldSellStr Sell
0m281611
-1m281611
-2m291611
-3m291512

Financial Statements

✓
Profitable
4/5 periods
✗
Revenue Growing
-1.6% latest, 1/3 up
✗
Earnings Growing
-3.2% latest, 1/3 up
✗
Pays Dividend
No dividends
✓
Positive Margin
6.8% net margin

Pfizer, Inc.

Healthcare \u00b7 Drug Manufacturers - General

Market Cap$151.73B
Trailing P/E35.0
Forward P/E9.2
EPS (trailing)$0.76
EPS (forward)$2.89
Gross Margin74.7%
Operating Margin27.9%
Profit Margin6.8%
Dividend Rate$1.72/share
Dividend Yield636.0%
Payout Ratio226.3%

Revenue & Net Income

2021 – 2025, Annual

Revenue

Net Income

Profit Margins

2021 – 2025, Annual

Earnings Per Share

2021 – 2025, Annual

Dividends

No dividend history available.

Income Snapshot 2025

Revenue
$62.6B
Net Income
$7.8B
Gross Margin
74.3%
Net Margin
12.4%
Op. Income
$17.4B
EPS
$1.37

Balance Sheet

2021 – 2025, Annual
Debt / Equity0.74x
Owns more than it owes — healthy
Current Ratio1.16x
Can cover short-term bills
Net Debt$62.82B
Total debt minus cash on hand

Assets vs Liabilities vs Equity

Assets = Liabilities + Equity. The green bar is what's left for shareholders after paying all debts.

Cash vs Debt

How much cash the company has on hand vs how much it owes in total debt.

Period Detail

PeriodAssetsLiabilitiesEquityCashDebtD/E
2021N/AN/AN/AN/AN/A—
2022$197.21B$101.29B$95.66B$416.0M$34.86B0.36x
2023$226.50B$137.21B$89.01B$2.85B$70.84B0.80x
2024$213.40B$124.90B$88.20B$1.04B$63.65B0.72x
2025$208.16B$121.39B$86.48B$1.14B$63.96B0.74x

Balance Sheet Snapshot 2025

Total Assets$208.16B
Total Liabilities$121.39B
Equity$86.48B
Retained Earnings$114.61B
Goodwill$71.26B
Long-Term Debt$60.81B

Cash Flow Statement

2021 – 2025, Annual

Operating · Investing · Financing

Operating — cash from core business.Investing — buying/selling long-term assets.Financing — debt, equity & dividends.

Free Cash Flow

Operating cash flow minus capital expenditure — the cash available after maintaining operations.

PeriodOperatingInvestingFinancingFCFCapEx
2021$0$0$0$0$0
2022$29B$-16B$-15B$26B$-3B
2023$9B$-32B$26B$5B$-4B
2024$13B$3B$-17B$10B$-3B
2025$12B$-1B$-10B$9B$-3B

Capital Allocation 2025

CapEx$2.63B
Dividends Paid$9.77B
BuybacksN/A
Debt Repaid$9.75B
Debt Issued$9.68B
Net Change Cash$49.0M
0∑×

Free market data & analysis tools.

Markets
HomeScreenerHeatmapSectorsEarnings
Tools
WatchlistCompareChart TerminalTechnical
Research
CongressInsidersDividendsCorrelation
© 2026 ShounyaAlpha v0.1.0Not financial advice · hanabira.org